Physicians' Academy for Cardiovascular Education

Cardiac abnormalities in recovered COVID-19 patients

3' education - July 29, 2020 - Prof. Rudolf de Boer, MD, PhD

MI more often missed in women

5' education - July 28, 2020 - Yldau van der Ende, MD, PhD

Getting better at diagnosing HFpEF - sharing clinical practice experience

15' education - July 28, 2020 - Prof. Mark Petrie, MD and Pardeep Jhund, MD, PhD

Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?

10' education - July 21, 2020 - Prof. Johannes Mann, MD

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD

Improving outcomes for patients following an admission with ADHF

15' education - July 7, 2020 - Prof. Mark Petrie, MD and Klaus Witte, MD

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

Tools to detect FH

10' education - June 23, 2020 - Rens Reeskamp, MD

DKD and CV risk: What is the potential of targeting GLP-1?

10' education - June 16, 2020 - Prof. Erik Stroes, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Mark Cooper, MD

Familial hypercholesterolemia in children and adolescents

10' education - June 2, 2020 - Bert Wiegman, MD, PhD

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands

Reduction of revascularization with icosapent ethyl in patients with hypertriglyceridemia

3' education - May 25, 2020 - Benjamin Peterson, MD

Increase in out-of-hospital cardiac arrest during the COVID-19 outbreak in Lombardy, Italy

3' education - May 8, 2020 - Enrico Baldi, MD

Venous thromboembolism in COVID-19 patients

5' education - May 6, 2020 - Prof. Saskia Middeldorp

Obesity as a risk factor for severity of COVID-19: multiple potential mechanisms

5' education - May 1, 2020 - Prof. Naveed Sattar, MD

SGLT2 inhibitor reduces risk of CV death or hospitalization in patients with HFrEF

News - Aug. 4, 2020

Results from the EMPEROR-Reduced trial showed that SGLT2 inhibitor empagliflozin significantly reduced the risk of CV death or hospitalization for heart failure in HFrEF patients with or without diabetes.

sGC stimulator gets priority review by FDA for HFrEF treatment

News - July 30, 2020

The FDA has accepted the new drug application for vericiguat for priority review. The sGC stimulator vericiguat is under development for the treatment of patients with chronic HF with ejection fraction <45%.

Cardiac abnormalities in recovered COVID-19 patients

3' education - July 29, 2020 - Prof. Rudolf de Boer, MD, PhD
Prof. De Boer discusses a recent paper in JAMA Cardiol on cardiac abnormalities detected by cardiovascular MRI in 100 patients who had proven COVID-19 around 2 months ago.

Prof. De Boer discusses a recent paper in JAMA Cardiol on cardiac abnormalities detected by cardiovascular MRI in 100 patients who had proven COVID-19 around 2 months ago.

SGLT2i efficacious and safe regardless of baseline ARNI treatment in HFrEF

Literature - July 29, 2020 - Solomon SD et al., - J Am Coll Cardiol Heart Fail. 2020.

In HFrEF patients from the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin was similarly efficacious and safe in those receiving ARNI treatment and those not receiving ARNI treatment.

Cardiac involvement and ongoing myocardial inflammation in recovered COVID-19 patients

Literature - July 28, 2020 - Puntmann VO et al., - JAMA Cardiol. 2020.

Cardiovascular MRI revealed cardiac involvement in 78% of patients and ongoing myocardial inflammation in 60% of patients in an unselected cohort of 100 patients who recently recovered from COVID-19.

Is chocolate good for the heart?

News - July 28, 2020
Results from a meta-analysis showed that higher chocolate consumption (>1 time per week or >3.5 times per month) may be beneficial for CAD risk reduction compared to no consumption or <1 time per week.

Results from a meta-analysis showed that higher chocolate consumption (>1 time per week or >3.5 times per month) may be beneficial for CAD risk reduction compared to no consumption or <1 time per week.

Management of bleeding on NOACs – an expert consensus decision pathway by ACC

News - July 28, 2020

The ACC Solution Set Oversight Committee has published a report with a decision pathway on how to manage bleedings in patients who used non-vitamin K oral anticoagulants (NOACs).

Primary and all secondary endpoint(s) met for SGLT2i in kidney outcomes trial

News - July 28, 2020

The SGLT2 inhibitor dapagliflozin reduced the primary endpoint and all secondary endpoints in the phase 3 DAPA-CKD trial, that enrolled CKD patients with and without T2DM.

MI more often missed in women

5' education - July 28, 2020 - Yldau van der Ende, MD, PhD
Although incidence of recognized and silent MI is higher in men, proportion of silent MI is greater in women when compared to men. Yldau van der Ende presents the design and findings of her study.

Although incidence of recognized and unrecognized MI is higher in men, proportion of unrecognized MI is greater in women when compared to men. Yldau van der Ende presents the design and findings of her study.

Getting better at diagnosing HFpEF - sharing clinical practice experience

15' education - July 28, 2020 - Prof. Mark Petrie, MD and Pardeep Jhund, MD, PhD
Two heart failure specialists from Glasgow, UK discuss a patient case to demonstrate that it can be difficult to diagnose HFpEF. They present tools that can help in the process of diagnosing HFpEF.

Two heart failure specialists from Glasgow, UK discuss a patient case to demonstrate that it can be difficult to diagnose HFpEF. They present tools that can help in the process of diagnosing HFpEF.

Elevated Lp(a) levels associated with increased risk of MACE when hsCRP ≥2 mg/L

Literature - July 27, 2020 - Puri R et al., - JAMA Cardiol. 2020.

Elevated Lp(a) levels were associated with greater risk of MACE in optimally treated patients with high-risk vascular disease when hsCRP levels ≥2 mg/L, but not in those with hsCRP levels <2 mg/L.

Catheter ablation reduces AF recurrence and AF burden

Literature - July 23, 2020 - Poole JE et al., - JACC 2020.

This expanded analysis of the CABANA trial showed that catheter ablation reduced symptomatic and asymptomatic AF recurrence and AF burden as compared to drug therapy over a 5-year follow-up period.